PATENT CLAIM ANALYSIS

Application Number: 16042833
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "04400A"]

Abstract:
In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

Claim (Index 44):
The method of  claim 31 , wherein the AMD is wet AMD.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15352322', '15220767', '15422122', '15422186', '15483305']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8163423259937231
- 35 USC 102 Novelty (BERT): 0.574833447712989
- Combined Prediction Score: 0.7921914381656497
- Mean Citation Score: 487.25584
- Max Citation Score: 738.3603
- Similarity Product: 346.6028420841784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test